Leerink Swann Upgrades Mylan (MYL) to Outperform
Tweet Send to a FriendGet Alerts MYL Hot Sheet
Price: $31.40 +2.28%
Rating Summary:
6 Buy, 5 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
6 Buy, 5 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade MYL Now!
Leerink Swann upgraded Mylan (NASDAQ: MYL) from Market Perform to Outperform with a price target of $30.00 (from $26.00).
The firm comments, "We are upgrading MYL to Outperform from Market Perform based on our increasing confidence for 3 key value drivers: (1) potential for sustained EpiPen sales beyond 2015 based on feedback from two MEDACorp regulatory specialists; (2) considerable financial flexibility to execute highly accretive M&A transaction(s); and (3) 2013 guidance that looks achievable & EPS upside vs. Street in 2014-15. Low visibility on US generics in 2013 remains a slight overhang but manageable in our view. We increase our EpiPen estimates, and our new valuation of $30/share (from $26) is based on our ’13E P/E multiple going to 11x (from 9.5x), supported by our DCF valuation."
For an analyst ratings summary and ratings history on Mylan click here. For more ratings news on Mylan click here.
Shares of Mylan closed at $25.50 yesterday, with a 52 week range of $17.22-$26.55.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm comments, "We are upgrading MYL to Outperform from Market Perform based on our increasing confidence for 3 key value drivers: (1) potential for sustained EpiPen sales beyond 2015 based on feedback from two MEDACorp regulatory specialists; (2) considerable financial flexibility to execute highly accretive M&A transaction(s); and (3) 2013 guidance that looks achievable & EPS upside vs. Street in 2014-15. Low visibility on US generics in 2013 remains a slight overhang but manageable in our view. We increase our EpiPen estimates, and our new valuation of $30/share (from $26) is based on our ’13E P/E multiple going to 11x (from 9.5x), supported by our DCF valuation."
For an analyst ratings summary and ratings history on Mylan click here. For more ratings news on Mylan click here.
Shares of Mylan closed at $25.50 yesterday, with a 52 week range of $17.22-$26.55.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Mylan (MYL) Launches Generic Tricor Tabs (ABBV)
- KeyBanc Upgrades Cedar Shopping Centers (CDR) to Hold
- Wells Fargo Downgrades Aruba Networks (ARUN) to Market Perform
Create E-mail Alert Related Categories
Upgrades
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
